Review

Control of autophagy by oncogenes and tumor suppressor genes

MC Maiuri^{1,2,3,4,5}, E Tasdemir^{1,2,3,5}, A Criollo^{1,2,3}, E Morselli^{1,2,3}, JM Vicencio^{1,2,3}, R Carnuccio⁴ and G Kroemer^{*,1,2,3}

Multiple oncogenes (in particular phosphatidylinositol 3-kinase, PI3K; activated Akt1; antiapoptotic proteins from the Bcl-2 family) inhibit autophagy. Similarly, several tumor suppressor proteins (such as BH3-only proteins; death-associated protein kinase-1, DAPK1; the phosphatase that antagonizes PI3K, PTEN; tuberous sclerosis complex 1 and 2, TSC1 and TSC2; as well as LKB1/STK11) induce autophagy, meaning that their loss reduces autophagy. Beclin-1, which is required for autophagy induction acts as a haploinsufficient tumor suppressor protein, and other essential autophagy mediators (such as Atg4c, UVRAG and Bif-1) are bona fide oncosuppressors. One of the central tumor suppressor proteins, p53 exerts an ambiguous function in the regulation of autophagy. Within the nucleus, p53 can act as an autophagy-inducing transcription factor. Within the cytoplasm, p53 exerts a tonic autophagy-inhibitory function, and its degradation is actually required for the induction of autophagy. The role of autophagy in oncogenesis and anticancer therapy is contradictory. Chronic suppression of autophagy may stimulate oncogenesis. However, once a tumor is formed, autophagy inhibition may be a therapeutic goal for radiosensitization and chemosensitization. Altogether, the current state-of-the art suggests a complex relationship between cancer and deregulated autophagy that must be disentangled by further in-depth investigation.

Cell Death and Differentiation (2009) 16, 87–93; doi:10.1038/cdd.2008.131; published online 19 September 2008

Autophagy constitutes one of the major responses of cells to external or internal stimuli. As any other major phenomenon of cell biology (such as division, differentiation and cell death), autophagy can be perturbed in cancer cells and is modulated by anticancer chemotherapies. The first functional link that has been established between autophagy and cancer originates from the landmark discovery that Beclin 1, a phylogenetically conserved protein that is essential for macroautophagy, is also a haploinsufficient tumor suppressor.¹ On the basis of this discovery and the observation that multiple stress signals including DNA damage can induce macroautophagy^{2–4} both fundamental and clinical oncologists have become aware of the possible importance of ‘self-eating’ for oncogenesis and therapeutic responses, thus launching a new area of febrile investigation.

Any biomedical investigator and clinical oncologist can enumerate the six cell-intrinsic hallmarks of cancer, as formulated by Hanahan and Weinberg,⁵ provision of autonomous growth signals, insensitivity to negative signals, limitless replication, production of angiogenic factors and tissue invasion with metastasis, as well as disabled apoptosis. In this context, it has been well established that prominent oncogenes reduce the propensity of cancer cells to undergo cell death, whereas prominent tumor suppressor proteins

have proapoptotic properties. However, the link between autophagy and cell death is highly ambiguous, and autophagy may serve as a mechanism of adaptation to stress (and hence avoidance of cell death), as well as, in special circumstances, as a route to cell death^{6–10} suggesting that the relationship between cancer and autophagy may be more complex than that between cancer and cell death.

The present review deals with autophagy regulation by oncogenes and tumor suppressor proteins and the contribution of deregulated autophagy may contribute to oncogenesis and tumor progression.

Regulation of Autophagy by the PI3K/Akt/mTOR Pathway

In cancer, essential signal-transducing molecules involved in growth signaling often are constitutively switched on due to activating mutation or due to the continuous presence of autocrine growth factors. Growth factors activate receptor tyrosine kinases (RTKs), which then stimulate two key signal transducing components: the small GTPase Ras and the phosphatidylinositol 3-kinase (PI3K). Ras and PI3K converge to activate mTOR for stimulating cell growth and for inhibiting autophagy. Most cancers harbor activating mutations of the

¹INSERM, U848, Apoptosis Cancer and Immunity, F-94805 Villejuif, France; ²Institute Gustave Roussy, F-94805 Villejuif, France; ³Université Paris Sud – Paris 11, F-94805 Villejuif, France and ⁴Università degli Studi di Napoli Federico II, Facoltà di Scienze Biotechnologiche, Dipartimento di Farmacologia Sperimentale, 80131 Napoli, Italy

*Corresponding author: Dr G Kroemer, INSERM U848, Institute Gustave Roussy, PR1, 39 rue Camille Desmoulins, F-94805 Villejuif, France.

Tel: 33 142 11 6046; Fax: 33 142 11 6047; E-mail: kroemer@igr.fr

⁵These authors equally contributed to this work.

Keywords: apoptosis; autophagy; Bcl-2; p53

Abbreviations: GFP, green fluorescent protein; NF, nutrient-free medium; PI, propidium iodine; siRNA, small interfering RNA; WT, wild type

Received 19.5.08; revised 24.6.08; accepted 17.7.08; Edited by G Melino; published online 19.9.08

master regulators (K-ras, H-Ras, N-ras, the p110a PI3K subunit and RTKs) or their downstream effectors (such as the kinases Akt and PDK1), or inactivating mutations in negative regulators of these proteins.¹¹ Germline mutation of such negative regulators, namely the Ras antagonist neurofibromin 1 (NF1), the mTOR inhibitors tuberous sclerosis complex 1 and 2 (TSC1, TSC2), LKB1 (a kinase that activates the AMP-activated protein kinase, AMPK) or the phosphatase PTEN, which reverses the phosphorylation mediated by PI3K, results in familial cancer syndromes. These pathologies share clinical features (phakomatoses or 'neurocutaneous syndromes'), characterized by hamartoma-type tumors (Peutz-Jegher's syndrome, tuberous sclerosis, Cowden's disease and neurofibromatosis type 1).¹¹

As a result, many cancers exhibit an enhanced activation of mTOR, resulting into reduced autophagy. Elegant *in vivo* experiments performed by White and colleagues⁴ demonstrate that constitutively active Akt inhibits the induction of autophagy *in vitro* and *in vivo*, whereas accelerating the growth of tumors *in vivo*, in particular in cells that lack the expression of Bax and Bak. This enhanced tumor growth could be correlated with an elevated level of tumor cell necrosis and local inflammation, as well as a marked genomic instability.¹² An important autophagy-regulatory gene, such as *Beclin 1*, functions as a haploinsufficient tumor suppressor gene. Deletion of one allele of Beclin-1 accelerates tumor growth *in vivo*, in the context of Bcl-2 overexpression.¹² In addition, monoallelic knockout of *beclin-1* or biallelic knockout of *atg5* had similar effects on genomic instability as constitutively active Akt.^{13,14} It appears plausible that the inhibition of autophagy is a major contributing factor in the oncogenic action of a constitutively active PI3K/Akt axis. Formal proof in favor of this possibility is however still elusive.

Regulation of Autophagy by Bcl-2 Family Proteins

Antiapoptotic proteins from the Bcl-2 family are prominent oncogenes, whereas proapoptotic proteins from this family are tumor suppressor proteins. Although Bcl-2 family proteins have been initially characterized as cell death regulators, it has recently become clear that they control the autophagic process as well. Thus, antiapoptotic proteins such as Bcl-2,¹⁵ Bcl-X_L,¹⁶ Bcl-w¹⁷ and Mcl-1¹⁶ can inhibit autophagy. Accordingly, the knockdown of Bcl-2 with antisense oligonucleotides¹⁸ or small interfering RNA (siRNA) heteroduplexes¹⁹ can induce autophagy in a range of different cell lines including leukemia and breast cancer cells. Conversely, proapoptotic BH3-only proteins from the Bcl-2 family, such as BNIP3L,^{20,21} Bad,¹⁶ Noxa, Puma, BimEL²² and Bik,²³ stimulate autophagy.

Beclin 1/Atg6 has initially been identified as a protein that interacts with Bcl-2.¹ Today, it is known that the essential autophagy protein Atg6/Beclin 1 cooperates with several cofactors (including Ambra-1, Bif-1 and UVRAG) to activate the lipid kinase Vps34, thereby inducing autophagy.^{24–27} In baseline conditions, Beclin 1 is bound to and inhibited by Bcl-2 or other antiapoptotic multidomain proteins of the Bcl-2 family including Bcl-X_L,¹⁶ Bcl-w¹⁷ and Mcl-1.¹⁶ At the structural level, it is important to note that antiapoptotic multidomain proteins possess a hydrophobic cleft, the so-called BH3 receptor domain, which can accommodate BH3 domains from

proapoptotic Bcl-2 protein family members. Such BH3 domains have an amphipathic α -helical structure.²⁸

Three different approaches have proven that Beclin 1 possesses a BH3 motif (aa 112–123). First, crystal structures have been obtained from recombinant Bcl-X_L protein complexed to a synthetic peptide that corresponds to the Bcl-2/Bcl-X_L-binding domain of Beclin 1. Similarly to previously determined Bcl-X_L-BH3 structures, the amphipathic BH3 helix of Beclin 1 binds to the BH3 receptor domain of Bcl-X_L.²⁹ Second, the X-crystallographic data have been confirmed by NMR spectroscopy.³⁰ Third, replacements of several critical amino acids within the putative BH3-only domain of Beclin 1 (L116A, L116E, L116Q, G120E, D121A and F123A) reduce or abrogate the molecular interaction between Beclin 1 and Bcl-X_L in GST pulldown, analytical gel filtration, fluorescence anisotropy measurements and/or coimmunoprecipitation assays.^{15,16,29–31} Altogether, these three technologies (X-crystallography, NMR and mutational analysis) convincingly demonstrate that Beclin 1 possesses a BH3 domain, if such domains are defined by their capacity to interact with the BH3 receptor domain of the antiapoptotic Bcl-2 proteins. It should be noted, however, that the overexpression of Beclin 1 cannot induce cell death (MCM and GK, unpublished observation), indicating that Beclin 1, in contrast to other BH3-only proteins, has no proapoptotic properties. Moreover, the incidence of tumors in mice carrying a knock-in mutation that modulates the BH3 domain of Beclin 1 has not been determined. Thus, the putative antioncogenic function of the BH3 domain of Beclin 1 remains elusive. In conclusion, the interaction between Beclin-1 and antiapoptotic proteins of the Bcl-2 family (in particular Bcl-2 and Bcl-X_L) involves the Bcl-2 homology 3 (BH3) domain in Beclin-1 and the BH3 receptor domain of Bcl-2/Bcl-X_L. Other proteins carrying BH3 domains can competitively disrupt the interaction between Beclin-1 and Bcl-2/Bcl-X_L to induce autophagy.³¹ Starvation from essential nutrients, which is the physiologically most potent inducer of autophagy, stimulates the dissociation of Beclin-1 from its inhibitors, presumably by activating the BH3-only protein, Bad.¹⁶ The BH3-mimetic compound, ABT737, an agent designed to occupy the BH3 receptor domain of Bcl-2 or Bcl-X_L (but not that of Mcl-1),³² also competitively disrupts the physical interaction between Beclin 1 and Bcl-2 or Bcl-X_L.³¹ ABT737 pretreatment abolishes the immunoprecipitation between Beclin 1 and Bcl-2 or Bcl-X_L (but not Mcl-1) in cells that are resistant to the proapoptotic action of ABT737. This effect correlates with the induction of massive autophagy. ABT737-induced autophagy cannot be inhibited by Bcl-2 or Bcl-X_L overexpression, yet is abolished by transfection with Mcl-1 or by the siRNA-mediated knockdown of Beclin 1.¹⁶ These results demonstrate that autophagy is efficiently triggered by the disruption of the interaction between Beclin 1 and Bcl-2 or Bcl-X_L.

Interestingly, ABT737 induces the autophagic sequestration of mitochondria (mitophagy) more efficiently than that of endoplasmic reticulum (ER; reticulophagy).¹³ Similarly, one particular BH3-only protein, BNIP3L, has been found to be required for the autophagic elimination of mitochondria that accompanies terminal erythroid differentiation.³³ Mitophagy induced by hypoxia occurs through the HIF-1-dependent transcriptional activation of BNIP3L, which disrupts the

interaction between Bcl-2 and Beclin.³⁴ These results point to the possibility that interactions between Bcl-2 family proteins and Beclin 1 have a particularly important function in the regulation of mitophagy.

Regulation of Autophagy by p53

The tumor suppressor protein p53 is often inactivated in tumor cells, for instance due to mutations of p53 itself, due to mutations of the kinases that lead to its activation (such as ATM or Chk1) or due to the amplification of MDM2, the E3 ubiquitin ligase that targets p53 to proteasome-mediated destruction.^{35,36} Hence, inactivation of the p53 system is one of the most frequent alterations that occur in cancer. p53 is mainly viewed as a transcription factor that transactivates proapoptotic and cell cycle-arresting genes,³⁶ thereby favoring apoptosis and senescence of cancer cell precursors (which explains its tumor-suppressive effects as a 'guardian of the genome') or of cancer cells that respond to chemotherapy or radiotherapy (which explains its positive impact on anti-cancer treatment). p53 can also transactivate an autophagy-inducing gene, *drain*, which codes for a lysosomal protein,³⁷ and p53-dependent induction of autophagy has been documented by several groups in response to DNA damage,³⁸ Arf activation,³⁹ or reexpression of p53 in p53-negative tumor cells.⁴⁰

Recently, we observed that inactivation of p53 by deletion, depletion or inhibition also can trigger autophagy.⁴¹ Thus, human and mouse cells subjected to knockout, knockdown or pharmacological inhibition of p53 manifest signs of autophagy, such as depletion of p62/SQSTM1, LC3 lipidation (and hence conversion of LC3-I into LC3-II), redistribution of GFP-LC3 in cytoplasmic puncta and electron microscopic evidence of autophagosomes and autolysosomes,⁴² both *in vitro* and *in vivo*.⁴¹ This applies to a variety of methods for p53 inactivation: chemical inhibition with cyclic pifithrin- α (PFT- α), knockdown with siRNAs specific for human p53, mouse p53 or the *Caenorhabditis elegans* p53 ortholog *cep1* or homologous recombination of p53 in human cancer cells, mice or nematodes. p53 inactivation was found to induce autophagy in several nontransformed or malignant human cell lines, namely HFFF2 fibroblasts, HCT116 colon cancer cells, SH-SY5Y neuroblastoma and HeLa cervical cancer cells, in mouse embryonic fibroblasts (MEF), *in vivo* in multiple mouse tissues (kidney, pancreas, liver, brain and heart), as well as in *C. elegans* embryos and adult pharyngeal cells.⁴¹ Electron microscopy and immunofluorescence experiments indicate that p53 inactivation induces both autophagy of the ER (reticulophagy) and mitochondria (mitophagy). When p53 was inhibited in an acute fashion by addition of PFT- α , reticulophagy was induced more rapidly than mitophagy, suggesting an intimate relationship between p53 inhibition and ER stress (which also induces preferential reticulophagy). Accordingly, p53 triggered the phosphorylation of eIF2 α , which is a hallmark of ER stress. Moreover, the knockdown or knockout of *IRE1*, one of the quintessential ER stress effectors, reduced autophagy induction by p53 inactivation.⁴¹

Inhibition of p53 caused autophagy in enucleated cells, indicating that the cytoplasmic, nonnuclear pool of p53 can regulate autophagy. We also observed that retransfection of

p53^{-/-} cells with wild-type (WT) p53 suppressed autophagy and that this effect could be mimicked by a p53 mutant that is excluded from the nucleus, due to the deletion of the nuclear localization sequence. In contrast, retransfection of *p53*^{-/-} cells with a nucleus-restricted p53 mutant (in which the nuclear localization sequence has been deleted) failed to inhibit autophagy. Hence, cytoplasmic (but not nuclear) p53 is responsible for the inhibition of autophagy. Several distinct autophagy inducers (e.g., nutrient depletion or addition of rapamycin, lithium, tunicamycin or thapsigargin) stimulated the rapid degradation of p53. The p53 protein was depleted both from the nucleus and from the cytoplasm, with similar kinetics. Inhibition of the p53-specific E3 ubiquitin ligase MDM2 (by two distinct pharmacological inhibitors or by knockdown) avoided p53 depletion and simultaneously prevented the activation of autophagy. Finally, a p53 mutant that lacks the MDM2 ubiquitinylation site and hence is more stable than WT p53 was particularly efficient in inhibiting autophagy.⁴¹

In conclusion, p53 has a dual function in the control of autophagy. On the one hand, nuclear p53 can induce autophagy through transcriptional effects. On the other hand, cytoplasmic p53 may act as a master repressor of autophagy. How this latter effect is achieved in mechanistic terms is not clear yet (Figure 1).

Regulation of Autophagy by DAPK

The death-associated protein kinase-1 (DAPK-1) is commonly silenced in human cancers by methylation, and has tumor and metastasis suppressor properties.⁴³ DAPK-1 also induces autophagy and apoptosis, through independent mechanisms. DAPK-1 interacts with the microtubule-associated protein MAP1B, in particular in conditions of amino-acid starvation. Autophagy induced by DAPK-1 overexpression is attenuated by knockdown of MAP1B,⁴⁴ suggesting that the interaction of DAPK1 with MAP1B (which in turn is capable of interacting with LC3) might be responsible for the induction of autophagy. MAP1B has been shown to inhibit autophagy in previous studies.⁴⁵ Future investigation will clarify whether MAP1B is the sole route that links DAPK1 to autophagy. Indeed, DAPK1 is an extremely pleiotropic molecule⁴³ and can activate the p53 system, suggesting that transcriptional programs influenced by DAPK1 might also affect the propensity of cells to undergo autophagy.

Deficient Autophagy as a Mechanism of Oncogenesis

Beclin 1 maps to a tumor susceptibility locus that is monoallelically deleted in a high percentage of human breast, ovarian and prostate cancers²⁴ (Table 1). Decreased expression of Beclin 1 has been observed in human breast, ovarian and brain tumors.^{24,50} The monoallelic deletions of *beclin 1* in human cancer likely contribute tumorigenesis, as targeted mutant mice with heterozygous disruption of *beclin 1* have decreased autophagy, spontaneously develop tumors including lymphomas, lung carcinomas, hepatocellular carcinomas and mammary precancerous lesions as they age, and undergo accelerated hepatitis B virus-induced carcinogenesis.^{51,52} Moreover, immortalized kidney and mammary

Figure 1 Cytoplasmic versus nuclear effects of p53. p53 has a Janus role in the control of autophagy. Nuclear p53 promotes the transcription of proapoptotic and cell cycle-arresting genes, and also can act as an autophagy-inducing transcription factor. In contrast, cytoplasmic p53 degradation exerts an autophagy-inhibitory function. Both of the p53 'faces' are not completely known at molecular level

Table 1 Germline or somatic mutations affecting autophagy in human cancer

Affected protein	Disease and putative link to autophagy	Reference
<i>Proteins that regulate autophagy</i>		
AKT, PI3K and PTEN	Neoplasia. Gain-of-function mutations or amplifications of PI3K and the protein kinase Akt (which activate mTOR) are frequent oncogenic alterations, whereas PTEN (the phosphatase that antagonizes PI3K) is often lost or silenced. These alterations confer autonomy from growth factors and suppress autophagy.	46
TSC1, TSC2	Tuberous sclerosis complex (autosomal dominant disorder with benign hamartomatous tumors in multiple organs). Can also be mutated at the somatic level. Mutations in TSC1 (hamartin) or TSC2 (tuberin) subvert their inhibition of mTOR, leading to mTOR activation and autophagy inhibition.	47
LKB1/STK11 (germline and somatic)	Peutz-Jegher's syndrome (autosomal dominant syndrome with benign hamartomatous polyps in gastrointestinal tract and increased incidence of epithelial cancers). Somatic mutations observed in nonsmall cell lung cancer. LKB1 is an intracellular energy sensor that activates AMPK and may stimulate autophagy by stabilizing p27.	48,49
p53 (somatic)	Cancer. Mutations in p53 are found in > 50% of all human tumors. Among multiple functions, p53 may activate autophagy after genotoxic stress and exert a tonic inhibition of autophagy in normal conditions.	38,37,40,41
<i>Proteins required for autophagy</i>		
Beclin 1 (somatic; monoallelic deletions)	Breast, ovarian and prostate cancer. Possibly due to genomic instability and/or deregulated cell growth.	1
UVRAG (somatic; monoallelic deletion)	Colorectal carcinoma	24

epithelial cells derived from *beclin 1* heterozygous-deficient mice are more aggressive than control cells derived from WT mice when they are inoculated into immunodeficient recipient mice.^{13,14} Other proteins that form part of the Beclin 1/class III PI3K complex, such as UVRAG and Bif1 may also act as tumor suppressors. UVRAG is monoallelically deleted at a high frequency in human colon cancers and, when over-expressed, suppresses the proliferation and tumorigenicity of

human colon cancer cells.²⁴ The deletion of *Bif1* in mice results in the development of spontaneous tumors. Finally, knockout of *atg4c*, a cysteine protease involved in the processing of LC3/Atg8, accelerates the development of methyl-cholanthrene-induced fibrosarcomas in mice⁵³ (Table 2). This suggests that tumor suppression may be a shared property of several distinct autophagy proteins that act at different steps in the pathway.

White and colleagues.⁴ have proposed two alternative (and nonexclusive) hypotheses to explain how the loss of autophagy may stimulate oncogenesis in spite of the fact that the suppression of autophagy enhances the frequency of necrotic cell deaths within tumors. First, enhanced necrosis due to suppressed autophagy might exacerbate local inflammation and thereby stimulate tumor growth.¹² Second, invalidated autophagy may promote genomic instability in metabolically stressed cells, leading to oncogene activation and tumor progression.^{13,14} Indeed, immortalized mouse epithelial cells that exhibit a genetically determined defect in

autophagy due to monoallelic loss of *beclin 1* or biallelic loss of *atg5* display increased DNA damage foci, centrosome abnormalities, numerical and structural chromosomal abnormalities and gene amplification, especially after ischemic stress. The mechanisms through which deficient autophagy may induce genomic instability are elusive. As a possibility, autophagy might simply be required for an optimal management of the bioenergetic flux, thus facilitating the minimum amount of ATP levels (and that of other metabolites) required for DNA repair.⁸ It is also possible that autophagy indirectly contributes to the enforcement of cell-cycle checkpoints by degrading

Table 2 Knockout genes affecting oncogenesis or cancer growth in mice

Genotype (organ)	Phenotype	Reference
<i>Germline mutations affecting the formation of autophagosomes</i>		
<i>Atg4C</i> ^{-/-}	Overall normal fetal and postnatal development. Tissue-specific diaphragmatic autophagy defect and reduced locomotor activity during starvation. Increased susceptibility to methylcholanthrene-induced fibrosarcomas.	53
<i>Atg6/Beclin 1</i> ^{+/-}	Increased frequency of spontaneous malignancies and mammary neoplastic lesions, accelerated development of hepatitis B virus-induced premalignant lesions, and hyperproliferation of mammary epithelial cells and splenic B lymphocytes.	51,52
<i>Bif-1</i> ^{-/-}	Enhanced frequency of spontaneous lymphomas, sarcomas and carcinomas required for autophagy in cell lines.	27
<i>p53</i> ^{-/-}	Enhanced frequency of cancers in multiple organs. Enhanced autophagy in most organs.	41
<i>Somatic manipulations affecting the formation of autophagosomes</i>		
<i>Myr-AKT</i> transgene (active AKT)	Inhibits autophagy and enhances the growth of Bax. <i>Bak</i> ^{-/-} immortalized baby mouse kidney epithelial (iBMK) cells <i>in vivo</i> promotes tumor necrosis.	12
<i>Beclin 1</i> ^{+/-}	Absence of one <i>Beclin 1</i> allele accelerates growth of iBMK tumors, in particular upon overexpression of Bcl-2, enhances tumor necrosis and local inflammation. Deletion of one <i>Beclin 1</i> allele is sufficient to strongly reduce autophagy in cell lines.	12

Figure 2 Autophagy in oncogenesis and anticancer therapy. The role of autophagy in oncogenesis is manifold. At the early stages of tumor, autophagy acts as a tumor suppressor. During tumor progression, autophagy can contribute to tumor growth. Further studies are necessary to elucidate the molecular mechanisms of this switch (a). Autophagy as a response to cancer therapy can promote/suppress tumor (b). Autophagy can be considered as an unusual target to improve anticancer therapy (c)

specific organelles or proteins that are essential for cell growth regulation.⁴¹ Finally, autophagy may be required to remove damaged organelles (such as mitochondria) and hence to regulate the levels of endogenous stress (including ROS production by uncoupled mitochondria),²⁶ meaning that deficient autophagy might affect genomic instability in a rather indirect fashion (Figure 2a).

Enhanced Autophagy as a Mechanism of Tumor Cell Survival

A large series of clinically approved and experimental anti-cancer therapies induce the accumulation of autophagosomes in tumor cell lines *in vitro*.⁷ For many years, it was thought that these therapies kill cells through autophagy and hence induce the so called 'autophagic cell death'. However, specific inhibition of autophagy with siRNA's targeted against ATG genes usually accelerates, rather than prevents, cell death in these settings,⁷ indicating that autophagy activation likewise represents a cellular attempt to cope with stress induced by cytotoxic agents.²⁶ Along these lines, inhibition of autophagy can be used for experimental cancer treatment. For example, in mice harboring c-Myc-induced lymphomas, the lysosomotropic drug chloroquine enhanced the efficacy of either p53 or a DNA alkylating agent to induce tumor cell death and tumor regression.⁴⁰

Inhibition of autophagy by siRNAs that target essential autophagy genes also sensitizes cancer cells to the induction of cell death by radiotherapy⁵⁴ and a wide range of chemotherapeutic agents including cyclophosphamide⁴⁰ and N-(4-hydroxyphenyl)retinamide.⁵⁵ Inhibition of autophagy also sensitizes breast cancer cells to killing by the estrogen receptor antagonist tamoxifen,⁵⁶ prostate cancer cells to androgen deprivation,⁵⁷ colon cancer cells to amino-acid or glucose deprivation,⁵⁸ Bax^{-/-} HCT116 cells to TRAIL-induced apoptosis⁵⁹ and multiple different cell lines to anoikis (apoptosis due to detachment from the extracellular matrix),⁶⁰ suggesting that suppression of autophagy could constitute a general strategy for rendering cancer cells more susceptible to the induction of cell death (Figure 2b and c).

Conclusions and Perspectives

As indicated in the introduction to this paper, cancer is characterized by six well-established hallmarks. There have been attempts to identify additional hallmarks, such as avoidance of immune control⁶¹ or increased anabolic reactions.⁶² As discussed here, however, the relationship between cancer and autophagy cannot be reduced to a simple formulation. As it stands, reduced autophagy maybe an oncogenic event and contribute to tumor progression, whereas enhanced autophagy may rather constitute a mechanisms through which tumor cells survive hypoxic, metabolic, detachment-induced or therapeutic stress.

Induction of autophagy, as it occurs in response to starvation, is responsible for the beneficial effects of caloric restriction on longevity, at least in *C. elegans*.⁶³ It is tempting to speculate that periodic induction of autophagy may also be responsible for the cancer preventive effect of caloric restriction. If this were true, pharmacological induction of

autophagy might be used for cancer chemoprevention. Therapeutic inhibition of autophagy, if feasible, might enhance the efficacy of radiotherapy or chemotherapy, yet might have an intrinsically co-oncogenic potential and stimulate tumor progression. Future will tell us how clinical oncologists will succeed to navigate between Scylla and Charybdis and in which particular tumors, in combination with which set of drugs, and in which therapeutic regimes, autophagy inhibitors or inducer will become efficient anticancer agents.

Acknowledgements. GK is supported by Ligue contre le Cancer, Agence Nationale pour la Recherche (ANR), Cancéropôle Ile-de-France, European Commission (Active p53, Apo-Sys, Chemores, TransDeath, Right, Death-Train), Fondation pour la Recherche Médicale, and Institut National du Cancer (INCa).

- Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H *et al.* Induction of autophagy and inhibition of tumorigenesis by beclin 1. *Nature* 1999; **402**: 672–676.
- Levine B. Cell biology: autophagy and cancer. *Nature* 2007; **446**: 745–747.
- Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. *Clin Cancer Res* 2007; **13**: 7271–7279.
- Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. *Nat Rev Cancer* 2007; **7**: 961–967.
- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000; **100**: 57–70.
- Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. *Nat Rev Cancer* 2005; **5**: 886–897.
- Maiuri MC, Zalcvar E, Kimchi A, Kroemer G. Self-eating and self-killing: cross talk between autophagy and apoptosis. *Nat Rev Mol Cell Biol* 2007; **8**: 741–752.
- Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N *et al.* Inhibition of macroautophagy triggers apoptosis. *Mol Cell Biol* 2005; **25**: 1025–1040.
- Galluzzi L, Miguel J, Kepp VO, Tasdemir E, Maiuri MC, Kroemer G. To die or not to die: that is the autophagic question. *Curr Mol Med* 2008; **8**: 78–91.
- Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. *Cell Death Differ* 2005; **2**: 1528–1534.
- Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature* 2006; **441**: 424–430.
- Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G *et al.* Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* 2006; **10**: 51–64.
- Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K *et al.* Autophagy suppresses tumor progression by limiting chromosomal instability. *Genes Dev* 2007; **21**: 1367–1381.
- Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S *et al.* Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. *Genes Dev* 2007; **21**: 1621–1635.
- Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N *et al.* Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. *Cell* 2005; **122**: 927–939.
- Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P *et al.* Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. *EMBO J* 2007; **26**: 2527–2539.
- Erich S, Mizrachi L, Segev O, Lindenboim L, Zmira O, Adi-Harel S *et al.* Differential interactions between Beclin 1 and Bcl-2 family members. *Autophagy* 2007; **3**: 561–568.
- Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G *et al.* Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. *Cell Death Differ* 2000; **7**: 1263–1269.
- Akar U, Chaves-Reyes A, Barria M, Tari A, Saungino A, Kondo Y *et al.* Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. *Autophagy* 2008; **4**: 669–679.
- Daïdo S, Kanzawa T, Yamamoto A, Takeuchi H, Kondo Y, Kondo S. Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells. *Cancer Res* 2004; **64**: 4286–4293.
- Hamacher-Brady A, Brady NR, Logue SE, Sayen MR, Jinno M, Kirshenbaum LA *et al.* Response to myocardial ischemia/reperfusion injury involves Bnip3 and autophagy. *Cell Death Differ* 2007; **14**: 146–157.
- Abidin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. *Cell Death Differ* 2007; **14**: 500–510.
- Rashmi R, Pillai SG, Vijayalingam S, Ryerse J, Chinnadurai G. BH3-only protein BIK induces caspase-independent cell death with autophagic features in Bcl-2 null cells. *Oncogene* 2008; **27**: 1366–1375.
- Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH *et al.* Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. *Nat Cell Biol* 2006; **8**: 688–699.

25. Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo S, Nardacci R *et al*. Ambra1 is a novel regulator of autophagy and controls nervous system development. *Nature* 2007; **447**: 1121–1125.
26. Rodríguez-Enríquez S, Kim I, Currin RT, Lemasters JJ. Tracker dyes to probe mitochondrial autophagy (mitophagy) in rat hepatocytes. *Autophagy* 2006; **2**: 39–46.
27. Takahashi Y, Coppola D, Matsushita N, Cuaing HD, Sun M, Sato Y *et al*. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. *Nat Cell Biol* 2007; **9**: 1142–1151.
28. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. *Nat Rev Cancer* 2008; **8**: 121–132.
29. Oberstein A, Jeffrey P, Shi Y. Crystal structure of the BCL-XL-beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. *J Biol Chem* 2007; **282**: 13123–13132.
30. Feng W, Huang S, Wu H, Zhang M. Molecular basis of Bcl-2's target recognition versatility revealed by the structure of Bcl-X_L in complex with the BH3 domain of Beclin-1. *J Mol Biol* 2007; **372**: 223–235.
31. Maiuri MC, Ciriello A, Tasdemir E, Vicencio JM, Tajeddine N, Hickman JA *et al*. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between beclin 1 and Bcl-2/Bcl-X(L). *Autophagy* 2007; **3**: 374–376.
32. Oltschdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA *et al*. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 2005; **435**: 677–681.
33. Schweers RL, Zhang J, Randall MS, Loyd MR, Li W, Dorsey FC *et al*. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. *Proc Natl Acad Sci USA* 2007; **104**: 19500–19505.
34. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB *et al*. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. *J Biol Chem* 2008; **283**: 10892–10903.
35. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature* 2000; **408**: 307–310.
36. Vousden KH, Lane DP. p53 in health and disease. *Nat Rev Mol Cell Biol* 2007; **8**: 275–283.
37. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR *et al*. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. *Cell* 2006; **126**: 121–134.
38. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. *Proc Natl Acad Sci USA* 2005; **102**: 8204–8209.
39. Abida WM, Gu W. p53-Dependent and p53-independent activation of autophagy by ARF. *Cancer Res* 2008; **68**: 352–357.
40. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI *et al*. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *J Clin Invest* 2007; **117**: 326–336.
41. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M *et al*. Regulation of autophagy by cytoplasmic p53. *Nat Cell Biol* 2008; **10**: 676–687.
42. Klionsky DJ, Cuervo AM, Seglen PO. Methods for monitoring autophagy from yeast to human. *Autophagy* 2007; **3**: 181–206.
43. Gozuacik D, Kimchi A. DAPK protein family and cancer. *Autophagy* 2006; **2**: 74–79.
44. Harrison B, Kraus M, Burch L, Stevens C, Craig A, Gordon-Weeks P *et al*. DAPK-1 binding to a linear peptide motif in MAP1B stimulates autophagy and membrane blebbing. *J Biol Chem* 2008; **283**: 9999–10014.
45. Wang QJ, Ding Y, Kohtz DS, Mizushima N, Cristea IM, Rout MP *et al*. Induction of autophagy in axonal dystrophy and degeneration. *J Neurosci* 2006; **26**: 8057–8068.
46. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. *Nat Rev Cancer* 2006; **6**: 184–192.
47. Schwartz RA, Fernandez G, Kotuliska K, Jozwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. *J Am Acad Dermatol* 2007; **57**: 189–202.
48. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P *et al*. LKB1 modulates lung cancer differentiation and metastasis. *Nature* 2007; **448**: 807–810.
49. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M *et al*. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. *Nat Cell Biol* 2007; **9**: 218–224.
50. Miracco C, Cosci E, Oliveri G, Luzzi P, Pacenti L, Monciatti I *et al*. Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumors. *Int J Oncol* 2007; **30**: 429–436.
51. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A *et al*. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *J Clin Invest* 2003; **112**: 1809–1820.
52. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. *Proc Natl Acad Sci USA* 2003; **100**: 15077–15082.
53. Marino G, Salvador-Montoliu N, Fueyo A, Knecht E, Mizushima N, Lopez-Otin C. Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/Autophagin-3. *J Biol Chem* 2007; **282**: 18573–18583.
54. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. *Cancer Res* 2008; **68**: 1485–1494.
55. Tiwari M, Bajpai VK, Sahasrabudhe AA, Kumar A, Sinha RA, Behari S *et al*. Inhibition of N-(4-hydroxyphenyl)retinamide-induced autophagy at a lower dose enhances cell death in malignant glioma cells. *Carcinogenesis* 2008; **29**: 600–609.
56. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB *et al*. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. *Breast Cancer Res Treat* 2008; in press.
57. Li M, Jiang X, Liu D, Na Y, Gao GF, Xi Z. Autophagy protects LNCaP cells under androgen deprivation conditions. *Autophagy* 2008; **4**: 54–60.
58. Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y *et al*. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. *Cancer Res* 2007; **67**: 9677–9684.
59. Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM *et al*. Involvement of protective autophagy in TRAIL-resistance of apoptosis defective tumor cells. *J Biol Chem* 2008; **283**: 19665–19677.
60. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. *Mol Biol Cell* 2008; **19**: 797–806.
61. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. *Nat Rev Immunol* 2008; **8**: 59–73.
62. Kroemer G, Pouyssegur J. Altered tumor cell metabolism: cancer's Achilles heel. *Cancer Cell* 2008; **13**: 472–482.
63. Toth ML, Sigmund T, Borsos E, Barna J, Erdelyi P, Takacs-Vellai K *et al*. Longevity pathways converge on autophagy genes to regulate life span in *Caenorhabditis elegans*. *Autophagy* 2008; **4**: 330–338.